Skip to main content Skip to main navigation menu Skip to site footer

The correlation TNF-α gene promoter region -238G, -308G, -857, and -1031 polymorphism with psoriasis vulgaris

  • Cashtri Meher ,
  • R. Lia Kusumawati Iswara ,
  • Irma D Roesyanto-Mahadi ,


Background: Psoriasis vulgaris is a recurrent chronic skin disorder signed by hyperproliferation and epidermal inflammation. One of the etiology of psoriasis is genetic factors related to genetic polymorphism as disease susceptibility markers. This study was aimed to analyze the correlation of TNF-α gene promoter region polymorphism with psoriasis vulgaris.

 Methods: An analytical observational study with cross-sectional design to identify correlation TNF-region promoter polymorphisms with psoriasis vulgaris. This study included 45 psoriasis vulgaris patients and 45 non-psoriasis vulgaris patients from April to October 2016 at Immuno-dermatology Polyclinic of Dermatology and Venereology/Haji Adam Malik Hospital, Medan. We isolated DNA from the blood sample then ran into the PCR process with specific primers. PCR results were examined by electrophoresis with 2% agarose. Chi-Square test was used to test the hypothesis of a relationship between the TNF-α promoter region and psoriasis vulgaris at a significance of P <0.05.


Result: Analysis by Chi-Square test found a significant correlation of polymorphism in TNF-α gene promoter region with psoriasis vulgaris in -308G (p=0,001) and 1031 (p=0,002) loci.

Conclusion: TNF-α gene promoter region polymorphism TNF-α gene -1031 was more frequent in the case group, -308G was commonly found in the control group. Both of them were significantly correlated with psoriasis vulgaris.


  1. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatology Venereol. 2003;17(3):257–70.
  2. Dogra A, Sachdeva S. Biologic therapy in psoriasis. Indian J Dermatology, Venereol Leprol. 2006;72(4):256.
  3. Gudjonsson J, Elder J. Psoriasis Vulgaris. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. p. 169–93.
  4. Wiryadi B. Epidemiologic data of psoriatic patient in Dr. Cipto Mangunkusumo General Hospital. In: Psoriasis CLEAR Study Group inaugural meeting. Singapore; 2004.
  5. Meher C, Iswara MK, Roesyanto-Mahadi ID. The role of single nucleotide Interleukin-6 (IL-6) polymorphism gene in Psoriasis vulgaris patients at Haji Adam Malik Central Hospital, Medan-Indonesia. Bali Med J. 2018;7(1):79–81.
  6. Schön MP. MD, and W.-Henning Boehncke, MD psoriasis; The Review Article. N Engl J Med. 2005;352:1899–912.
  7. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003;21(5):392–7.
  8. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–26.
  9. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumour necrosis factorâ€alpha (TNFâ€Î±) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96(1):146–51.
  10. Steinhoff M, Luger T. The skin cytokine network. In: Bos J, editor. Skin. 3rd ed. Amsterdam: CRC Press LCC; 2005. p. 349–72.
  11. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol. 2004;51(4):563–9.
  12. Bos JD. Skin immune system: Cutaneous immunology and clinical immunodermatology. CRC press; 2004.
  13. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Heal Pharm. 2000;57(7):645–59.
  14. Feldman S. Psoriasis. In: Handout of American Academy Dermatology Congress. 2006.
  15. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol. 2007;25(6):563–7.
  16. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653–61.
  17. Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol. 2009;129(4):827–33.
  18. Gudjonsson JE. Genetic variation and psoriasis. G Ital di dermatologia e Venereol organo Uff Soc Ital di dermatologia e Sifilogr. 2008;143(5):299–305.
  19. Pociot F, D’alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol. 1995;42(4):501–4.
  20. Wilson AG, Di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNFα) gene detectable by Ncol restriction of PCR product. Hum Mol Genet. 1992;1(5):353.
  21. Llanos C, Soto L, Sabugo F, Bastias M, Salasar L, Aguillón J. Papel de los polimorfismos -238 y -308 del promoter del factor de necrosis tumoral alfa en la patogenia y respuesta a tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide. Rev Méd Chile. 2005;133:1089–95.
  22. Oregón-Romero E, Vázquez-Del Mercado M, Ruiz-Quezada L, Navarro-Hernández R, Rangel-Villalobos H, Martínez-Bonilla G. Tumor necrosis factor α-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-α. J Invest Med. 2008;56:937–94.
  23. Rácz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med. 2009;11.
  24. Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A. Tumor necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2004;33:228–32.
  25. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D. Tumor necrosis factor (TNF) alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35:435–40.
  26. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007;57:1426–30.
  27. Seitz M, Wirthmüller U, Möller B, Villiger P. The -308 tumor necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatol. 2007;46:93–6.
  28. Rahman P, O'Rielly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. 2008;
  29. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67(4):478–84.
  30. Kang CP, Lee K-W, Yoo D-H, Kang C, Bae S-C. The influence of a polymorphism at position− 857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology. 2005;44(4):547–52.
  31. Coenen MJH, Toonen EJM, Scheffer H, Radstake TRDJ, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. 2007;
  32. Li C, Wang G, Gao Y, Liu L, Gao T. TNF-α gene promoter-238G> A and-308G> A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol. 2007;127(8):1886–92.
  33. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, et al. Different transcriptional activity and in vitro TNF-α production in psoriasis patients carrying the TNF-α 238A promoter polymorphism. J Invest Dermatol. 2000;114(6):1180–3.
  34. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.
  35. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–41.
  36. Sinniah B, Saraswathy Devi PS, Prashant BS. Epidemiology of psoriasis in Malaysia: a hospital based study. Med J Malaysia. 2010;65(2):112–4.
  37. Djuanda A, Hamzah M, Aisah S. Ilmu penyakit kulit dan kelamin. Jakarta Fak Kedokt Univ Indones. 2007;3–8.
  38. Gallo E, Cabaleiro T, Román M, Abad-Santos F, Daudén E. Study of genetic polymorphisms in the tumor necrosis factor α promoter region in Spanish patients with psoriasis. Actas Dermo-Sifiliográficas (English Ed. 2012;103(4):301–7.
  39. Zhuang L, Ma W, Cai D, Zhong H, Sun Q. Associations between tumor necrosis factor-α polymorphisms and risk of psoriasis: a meta-analysis. PLoS One. 2013;8(12):e68827.
  40. Reich K, Hüffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*â€857 independent of the PSORS1 risk allele. Arthritis Rheum. 2007;56(6):2056–64.
  41. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag U, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 2001;1(4):272–87.

How to Cite

Meher, C., Iswara, R. L. K., & Roesyanto-Mahadi, I. D. (2021). The correlation TNF-α gene promoter region -238G, -308G, -857, and -1031 polymorphism with psoriasis vulgaris. Bali Medical Journal, 10(1), 126–131.




Search Panel

Cashtri Meher
Google Scholar
BMJ Journal

R. Lia Kusumawati Iswara
Google Scholar
BMJ Journal

Irma D Roesyanto-Mahadi
Google Scholar
BMJ Journal